Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergen labeling guidance

This article was originally published in The Tan Sheet

Executive Summary

"Is a major food allergen that has been unintentionally added to a food as a result of cross-contact subject to FALCPA's labeling requirements?" is a question FDA answers in the second edition of its industry guidance on the Food Allergen Labeling & Consumer Protection Act of 2004. According to the document, major food allergens that are "unintentionally" added to a food due to cross-contact are not subject to FALCPA labeling requirements. The agency first released the question-and-answer guidance in October and expects to issue new editions as more questions are posed by industry (1"The Tan Sheet" Oct. 24, 2005, p. 10). The deadline for FALCPA labeling compliance is Jan. 1...
Advertisement

Related Content

FDA Guidance Clarifies Labeling For Supplements Containing Food Allergens
FDA Guidance Clarifies Labeling For Supplements Containing Food Allergens

Topics

Advertisement
UsernamePublicRestriction

Register

PS098928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel